aibioKymera Therapeutics
Top story · Jul 27, 2026 · SEC filing 8-K
Kymera Therapeutics reports a leadership change
Gollob will continue providing services to the Company as an advisor until December 31, 2026.
- Ticker
- KYMR
- Listing
- NASDAQ, United States
- Next date
- Oct. 29, 2026
- Chief executive
- Nello Mainolfi, Ph.D. (founder, president and CEO)
Desk view · Opinion · Updated Oct 22, 2026
Kymera's pill-for-Dupixent bet faces its first real test
Kymera has the cash to run its plan into 2029 and a lead drug aimed at a pathway that already works in the clinic. What it lacks is randomized proof that a STAT6 degrader pill can do what Dupixent does. The BROADEN2 readout at year-end is the event that decides how this desk reads in 2027.
Read the full desk viewaibio.space Investor Rank · Opinion
5/10 Neutral view
Funded into 2029, but KT-621 has no randomized efficacy data and a weak BROADEN2 result at year-end would undercut both the lead drug and the platform.
- Technology
- 1/2
- Odds
- 1/2
- Balance sheet
- 2/2
- Risk
- 0/2
- Momentum
- 1/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Promising, not yet proven. KT-621 degraded STAT6 deeply in a small open-label study, but no randomized efficacy data exist yet.
- Odds
- Phase 2b test pending. BROADEN2 reads out by year-end 2026 with early data benchmarked against dupilumab; 28.9% of phase 2 programs reach phase 3 historically.
- Balance sheet
- Strong. Kymera held $1.5 billion at June 30, 2026 and guides to runway into 2029.
- Main risk
- One readout carries the story. A weak BROADEN2 result would undercut the lead asset and the platform case.
- Watch next
- Year-end eczema data. BROADEN2 topline results are due by year-end 2026, with KT-579 phase 1 data in Q4.
Top news on Kymera
Questions investors ask
What is aibio.space's Investor Rank for Kymera Therapeutics?
5 out of 10, our neutral view. Funded into 2029, but KT-621 has no randomized efficacy data and a weak BROADEN2 result at year-end would undercut both the lead drug and the platform. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
What does Kymera Therapeutics do?
Kymera develops oral small molecule drugs that degrade disease-causing proteins, an approach called targeted protein degradation. Its pipeline is focused on immunological diseases. Source
When are KT-621 phase 2b results expected?
Kymera expects topline data from BROADEN2, its phase 2b trial in atopic dermatitis, by year-end 2026, after enrollment finished six months early. Asthma data from BREADTH are expected in late 2027. Source
How much cash does Kymera have?
Kymera reported $1.5 billion in cash, cash equivalents and investments at June 30, 2026. It expects the money to fund operations into 2029. Source
Who is Kymera's CEO?
Nello Mainolfi, Ph.D., is Kymera's founder, president and CEO. Felix Baker became board chairman in June 2026. Source
What are Kymera's partnerships with Sanofi and Gilead?
Sanofi runs the IRAK4 degrader KT-485 and paid a $20 million milestone when phase 1 dosing began in June 2026, with up to $975 million more possible. Gilead exercised its option on CDK2 degrader KT-200 in April 2026 for $45 million, with up to $665 million more in milestones. Source
What is Kymera Therapeutics's market cap?
We do not publish live share prices. In its annual report, Kymera Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $2.29 billion as of Dec 31, 2025. Source
Is Kymera Therapeutics a smaller reporting company?
SEC records list Kymera Therapeutics, Inc.'s filer category as: Large accelerated filer. Source
Where is Kymera Therapeutics headquartered?
SEC records list its business address as 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472. Source
When does Kymera Therapeutics's fiscal year end?
Kymera Therapeutics, Inc.'s fiscal year ends on December 31, per SEC records. Source
What did Kymera Therapeutics last file with the SEC?
Its most recent filing in our record is a 10-Q filed 2026-08-05. All of its filings are on SEC EDGAR. Source
What was Kymera Therapeutics called before?
SEC records list these former names: Kymera Therapeutics, Inc.. Source
What industry is Kymera Therapeutics in?
Its SEC industry code (SIC 2836) is Biological Products, (No Diagnostic Substances). Source
Legal and investor matters
The Commitments and Contingencies note in the 10-Q filed 2026-08-05 states: "The Company is not currently a party to any legal proceedings." Source
- Governance
Kymera chief medical officer Jared Gollob resigns; Terence Rooney succeeds him
Kymera reported that Jared Gollob communicated his intention to retire as chief medical officer and submitted his resignation on 2026-07-27, and will advise the company until 2026-12-31. The 8-K says Dr. Gollob informed the company he resigned for personal reasons and not as the result of any disagreement with the company's practices or policies. Terence Rooney succeeds him as CMO effective 2026-07-27.
- Governance
Kymera board adopts federal-court exclusive forum bylaw for securities claims
On 2026-03-25 Kymera's board approved a bylaw amendment, effective immediately, designating the federal district courts as the exclusive forum for complaints asserting claims under the Securities Act of 1933 and the Securities Exchange Act of 1934, unless the company consents to another forum. The board said it acted in response to recent amendments to Delaware corporate law on forum selection provisions.
- Financing
Kymera signs $500 million at-the-market sales agreement with TD Cowen
On 2026-02-26 Kymera entered a sales agreement with TD Securities (USA) LLC for an at-the-market program under which it may sell common stock with an aggregate offering price of up to $500,000,000. The company is not obligated to sell any shares. The same day Jefferies accepted the company's notice terminating the earlier Open Market Sale Agreement dated 2024-10-31.
- Financing
Kymera prices 7 million share follow-on offering at $86.00
Kymera entered an underwriting agreement on 2025-12-09 to sell 7,000,000 shares of common stock at $86.00 per share. On 2025-12-10 the underwriters exercised in full their option for 1,050,000 additional shares. The company estimated net proceeds of approximately $656.1 million and said it would use them to advance its degrader pipeline.
- Financing
Kymera prices follow-on offering at $44.00 with pre-funded warrants
Kymera entered an underwriting agreement on 2025-06-26 to sell 5,044,500 shares of common stock at $44.00 per share and pre-funded warrants for up to 655,500 shares. The underwriters held a 30-day option for 855,000 additional shares. The company estimated net proceeds of approximately $237.3 million, or $272.7 million if the option is exercised in full.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| KT-621 (oral STAT6 degrader) | Moderate to severe atopic dermatitis (BROADEN2) | Phase 2b, enrollment complete; topline data by year-end 2026 Source |
| KT-621 (oral STAT6 degrader) | Moderate to severe eosinophilic asthma (BREADTH) | Phase 2b, enrolling; data late 2027 Source |
| KT-579 (oral IRF5 degrader) | Lupus and other autoimmune diseases | Phase 1 in healthy volunteers; data Q4 2026 Source |
| KT-485 / SAR447971 (oral IRAK4 degrader, Sanofi) | Immuno-inflammatory diseases, including hidradenitis suppurativa | Phase 1 (started June 2026, run by Sanofi) Source |
| KT-200 (oral CDK2 molecular glue degrader, Gilead) | Breast cancer and other solid tumors | Preclinical; Gilead plans IND filing in 2027 Source |
Stock chart
SEC filings and registration
- SEC name
- Kymera Therapeutics, Inc.
- CIK
- 1815442
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- KYMR (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Phone
- 857-285-5314
- Shares outstanding
- 83,150,618 as of 2026-07-31 (10-Q filed 2026-08-05)
- Former names
- Kymera Therapeutics, Inc.
Recent filings
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction